⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926726 | 0.73 | — | — | |
| SCHEMBL3926728 | 0.71 | MAPT (0.39) | — | |
| SCHEMBL2101989 | 0.69 | — | — | |
| SCHEMBL19968205 | 0.67 | — | — | |
| SCHEMBL13623711 | 0.64 | — | — | |
| SCHEMBL22219448 | 0.64 | — | — | |
| SCHEMBL1833058 | 0.64 | — | — | |
| SCHEMBL24079338 | 0.62 | — | — | |
| SCHEMBL7056257 | 0.62 | — | — | |
| Iodide SCHEMBL3387682 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066296-A1 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4448490-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | Alexion Pharmaceuticals, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118382616-A | Synthesis method of complement factor D inhibitor and intermediate thereof | 阿雷克森制药公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-10801105-B2 | Process for the generation of thin inorganic films | BASF SE (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| EP-1423380-B1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-1423382-B1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-04-16 | — | — | EP | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6306883-B1 | NOVEL PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND AND INHIBITING CYTOKINES BY A COMPOUND OF FORMULA (I) AND THE TREATMENT OF CYTOKINES MEDIATED DISEASES, | SMITHKLINE BEECHAM CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-5998425-A | CYTOKINE ANTAGONIST; ANTIARTHRITIC AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0871622-A4 | — | — | 1998-10-21 | — | — | EP | disclosed |
| EP-0871622-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1995031451-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-11-23 | — | — | WO | disclosed |
| US-4341720-A | FROM AN OXALIC ACID COMPOUND AND PHOSPHORUS PENTACHLORIDE IN PRESENCE OF A TERTIARY AMINE COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1982-07-27 | — | — | US | disclosed |
| EP-0009658-A1 | Process for the preparation of oxalyl chloride | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |